Galmed Pharmaceuticals Ltd (GLMD) Quote

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

GLMD new 52=week low

GLMD new 52 week low

GLMD new 52 week low

GLMD new 52 week low

GLMD new 52 week low

GLMD new 52 low

GLMD new 52 week low

https://stockcharts.com/h-sc/ui?s=glmd&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/glmd/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/glmd/opinion

https://finance.yahoo.com/quote/GLMD?p=GLMD

https://www.nasdaq.com/market-activity/spos

$1.25 offering

Lol caught a falling knife

$GLMD - ??Up 20% Pre-Market/ Current Price $2.91
To employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Woot woot

Nice

https://www.prnewswire.com/news-releases/galmed-announces-initiation-of-a-clinical-development-program-to-evaluate-aramchol-meglumine-for-the-treatment-of-primary-sclerosing-cholangitis-psc-301819268.html

https://ih.advfn.com/stock-market/NASDAQ/galmed-pharmaceuticals-GLMD/historical

https://stockcharts.com/h-sc/ui?s=glmd&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/glmd/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/glmd/opinion

Open gap on the chart at .30

$GLMD Galmed Pharmaceuticals forms a Strategic Partnership with OnKai

https://galmedpharma.investorroom.com/2023-05-04-Galmed-Pharmaceuticals-forms-a-Strategic-Partnership-with-OnKai

any idea what the deal is here?

wow!

Wow no one posted anything on this move today shocker

Decent move ..thus far today!! Like it!!

Ah... news... starting dosing!!..

Well.... guess it depends on definitions!! I see a 20-40 % gain in less than 4-6 months!! The more than 3x some are expecting.... will probably be longer!!

I agree ... better to have strong institutional interest (as per recent activity after KOL event) than here but I think it'll still be a year or so before this stock really takes off

Nice day again!! And no interest here!! HEY ok with me!! LOL

Nice move today!! Nice volume also!!

Volume was up 3x normal yesterday on 12/15. The 100 day moving average was also breached suggestive of something cooking. Very exciting company; interesting to see where this goes

* * $GLMD Video Chart 12-04-2019 * *

Link to Video - click here to watch the technical chart video

GLMD phase-2b data NASH data:

https://finance.yahoo.com/news/phase-2-data-galmed-pharmaceuticals-163000034.html

GLMD 3Q18 results—cash=$92.3M:

https://finance.yahoo.com/news/galmed-pharmaceuticals-provides-business-reports-120000693.html

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2018 Results - Earnings Call Transcript $GLMD

https://seekingalpha.com/article/4194869

The final cost of the trial will be around $75 million
200 centers
Start by Q2-2019
Duration 52 weeks
No of patients - around 300

Study enrollment may take 12-18 months + 12 months + 3-4 months for topline results - we are looking at 32-36 months or 3 years - which is Q2-2022

If there is no buyout or partnership - we will see just dilution and SP going down

GLMD 2Q18 CC notes re phase-3 NASH trial:

https://twitter.com/DewDiligence/status/1025045825884438530

GLMD 2Q18 results:

https://finance.yahoo.com/news/galmed-pharmaceuticals-provides-business-reports-110000942.html

6/30/18 cash was $94.1M.

GLMD chart

Thinking to put 20k in it for long run. Raitings are great.

Galmed Notches Second Bullish Rating On Aramchol Opportunity
10:49 am ET July 13, 2018 (Benzinga) Print
Two days after Cantor Fitzgerald gave Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) a shot in the arm with an ultrabullish rating, Stifel Nicolaus administered a booster.

Galmed spiked 15 percent Friday morning after already having risen 21 percent in the preceding session.

The Analyst

Stifel analyst Adam Walsh initiated coverage of Galmed with a Buy rating and $35 price target.

The Thesis

As with Cantor Fitzgerald, Galmed’s Aramchol was again the point of optimism.

Walsh considers the candidate a multibillion-dollar opportunity for the treatment of non-alcoholic steatohepatitis, or NASH, and forecast a “decent chance” of an Aramchol partnership deal materializing ahead of the Phase 3 trial launch in the first half of 2019. (See Walsh's track record here.)

“We think large-pharma validation could drive shares significantly higher,” the analyst said.

With positive Phase 2b results failing to stimulate the stock, Stifel said the Street overlooked Aramchol’s strengths and thereby created a buying opportunity.

Aramchol did not reach statistical significance on either of two approvable endpoints — but they were secondary endpoints and were not powered for statistics, Walsh said.

“While Aramchol did not hit statistical significance on either of the two approvable endpoints, we remind investors that these “Despite this, Aramchol nearly hit on NASH resolution without worsening of fibrosis and showed strong trends on the fibrosis improvement with no worsening of NASH.”

The analyst expects the next phase to generate the statistically significant data investors demand.

After conversations with management, Walsh rejected concerns over dropout rates and competition from Madrigal Pharmaceuticals Inc (NASDAQ: MDGL).

Price Action

Galmed shares were rallying 16.27 percent to $14.85 at the time of publication Friday morning.

Related Links:

Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate

Zogenix Soars On Positive Phase 3 Data In Dravet Syndrome Study

Photo by Nephron/Wikimedia.

Latest Ratings for GLMD DateFirmActionFromTo

Jul 2018Stifel NicolausInitiates Coverage OnBuy Jul 2018Cantor FitzgeraldInitiates Coverage OnOverweight Jun 2018Maxim GroupMaintainsBuyBuy

15.39 > very bullish!

Heading back to $20.00+ very,very,soon!

Galmed Pharmaceuticals started at buy with $35 stock price target at Stifel Nicolaus
7:26 am ET July 13, 2018 (MarketWatch)
Share
Print
(END) Dow Jones Newswires

July 13, 2018 07:26 ET (11:26 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

Price Target Announced at $59.00/Share by Cantor Fitzgerald

Ratings actions from Benzinga: http://www.benzinga.com/stock/GLMD/ratings

(END) Dow Jones Newswires

July 11, 2018 16:24 ET (20:24 GMT)

GLMD sells 5.75M* shares @$15.00—a 9% discount to last Friday’s close:

https://finance.yahoo.com/news/galmed-pharmaceuticals-ltd-announces-pricing-013700954.html

Net proceeds from the offering will be about $81M*.

*Assuming exercise of underwriter’s option.

GLMD updates patent information:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418034494/tv496661_ex99-3.htm

GLMD seeking $86.3M* on unspecified terms:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418034494/tv496661_ex99-2.htm

A new corporate slide deck has been issued to accompany the above PR:
https://www.sec.gov/Archives/edgar/data/1595353/000114420418034494/tv496661_ex99-1.htm

*Assuming exercise of underwriter’s option.

Out at $21.20's. GL everyone.

shorted a handfull at $22...just got out when she dipped under $19...may go long later.....glta

Back in here in the 19's and 20's for round 2 ahead. Todays run from pre market $10 to $12 to over $27.00 after the open was insane! Hope we do it again this afternoon. The float is gone now. Looks like the walkdown is buyers with tight stop losses on the drop;

I was waiting for your pal CJ to show up here

Awesome pre market. Out here. GL everyone.

GLMD PR on phase-2b ARREST study in NASH:

https://finance.yahoo.com/news/galmeds-600-mg-aramchol-achieved-110000752.html

Trading float is 10.6 million shares, according to MarketWatch.